Figure 6 | Scientific Reports

Figure 6

From: Anti-CfaE nanobodies provide broad cross-protection against major pathogenic enterotoxigenic Escherichia coli strains, with implications for vaccine design

Figure 6

IgA Fc fusion enhances in vivo potency of 2R215 and 1D7. (A) Cartoon representation of pre-treatment protocol of VHH administration. VHH are administered one or two hours prior to administration of 107 CFU of H10407. Animals are euthanized 24 h after challenge, and bacterial colonies in the small intestine are counted. (B,C) DBA/2 mice were challenged intragastrically with 107 CFU of H10407 pre-incubated with 10 mg/kg of fusionbody. Treatment with 1D7 VHH-IgA1 resulted in 3.5 log reduction in CFU, P < 0.001) and 2R215 VHH-IgA2 in 5 log reduction in CFU (P < 0.001). (D) Fusionbodies 2R215 and 1D7 were intragastrically administered one hour prior to administration of 107 CFU of H10407. Fusionbody pre-treatment resulted in reduction of CFUs by 1.2 log for 2R215 VHH-IgA2 (P < 0.01) and 2.7 log for 1D7 VHH-IgA1 (P < 0.0001). Two biological replicates were performed. (E,F) Fusionbodies 2R215 and 1D7 and Travelan were intragastrically administered two hours prior to administration of 107 CFU of H10407. A 1.7 log reduction in total CFUs was observed in 1D7 VHH-IgA1 treated animals as compared to the group treated with irrelevant control (P < 0.0001). Two biological replicates were performed.

Back to article page